A potential strategy to overcome DCK deficiency‐mediated nucleoside drug resistance is using nucleoside analog phosphate prodrugs with anticancer efficacy without the demand for DCK phosphorylation,36 among which NUC‐1031, a gemcitabine phosphoramidate prodrug, has entered clinical trials for the treatment of gemcitabine‐resistant cancers.37, 38. The gene discussed is DCK; the disease is cancer.